LYEL logo

LYEL Lyell Immunopharma, Inc.

NASDAQ · Biotechnology · Healthcare

$13.80
+0.22 (+1.62%)

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company’s lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a…

Market Cap: $339.28Mwww.lyell.com

Price

No data yet.

Social Signal Score

46
5d
—
30d
45
5 mentions
—
60d
47
6 mentions
—
90d
47
6 mentions
—
news: 6

Analyst Ratings

7 analysts
Buyconsensus
Strong Buy 0Buy 3Hold 3Sell 1Strong Sell 0
Avg price target$39.5+186.2%
Low $34Median $39.5High $45
Current Consensus

Revenue

$3.0K-99.76%
$2.0K$16.13M$32.26M$48.39M
Mar 2020Sep 2026

Analyst Estimates

FY2025
$-10.53
$-10.56–$-10.49
3 analysts
FY2026
$-6.80
$-7.09–$-6.45
4 analysts
FY2027
$-6.57
$-9.28–$-4.25
4 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Lynn Seely
Sector
Healthcare
Industry
Biotechnology
Employees
161
Beta
-0.07
Country
US
Piotroski score
1 / 9 (Weak)
Altman Z-score
-8.82
www.lyell.com